Novel coronavirus O'Micron discovered for the first time in China

On Dec. 14, authorities in the northern port city of Tianjin said they had detected the novel coronavirus O'Micron mutant in one person, the first time it has been found in mainland China.

The Tianjin municipal government said in a statement on its verified social media account that the case was a traveler who entered the city from overseas on December 9.

First-line treatment of lung cancer! Anti-PD-L1 McAb of Cornerstone Pharmaceutical is expected to be approved in the near future.

China's State Drug Administration (NMPA) recently announced that Cornerstone Pharmaceutical's application for a new drug against PD-L1 monoclonal antibody sulgarizumab (NDA) has entered: it is under examination and approval, which means the new drug is expected to be approved in China in the near future.

According to public data, the indications for sulgarizumab are expected to be approved for first-line chemotherapy in patients with advanced squamous and non-squamous non-small cell lung cancer (NSCLC).

Pfizer Inc spends about $6.7 billion to expand immune inflammatory disease pipeline

On December 13th, Pfizer Inc (Pfizer) and Arena Pharmaceuticals jointly announced that they had reached an agreement. Pfizer Inc will buy Arena for about $6.7 billion.

Arena's research and development pipeline includes a variety of drug candidates in gastroenterology, dermatology and cardiology, includingEtrasimod is an oral, selective sphingosine 1-phosphate (S1P) receptor modulator, which is currently being developed for the treatment of a range of immuno-inflammatory diseases, including gastrointestinal and skin diseases.

Since then, Arena shares have risen more than 80 per cent.

CD22 ADC: Pfizer Inc's "Izhu Monoclonal Antibody Ozomixin" is about to be approved

On December 13, Pfizer Inc entered the administrative examination and approval stage for the listing of CD22's ADC drug Izumab oxazolamicin, which is expected to be approved in the near future for recurrent or refractory CD22-positive acute lymphoblastic leukemia (ALL).

Izumab is an antibody-drug conjugate (ADC), which is coupled with the cytotoxic preparation kazithromycin by monoclonal antibody (mAb) targeting CD22.

First-line treatment of lung cancer failed! Merck & Co Inc / Eisai "immunity + targeting" combination was badly hit.

Merck & Co Inc Keytruda is the king in tumor immunotherapy, with sales of $12.578 billion in the first three quarters of this year.

In March 2018, Merck & Co Inc signed a $5.8 billion cooperation agreement with Eisai to develop oral multireceptor tyrosine kinase inhibitor Lenvima monotherapy and combination therapy with Keytruda.

Data from the project show that the combination has shown strong efficacy in many types of tumors, but has suffered a major setback in lung cancer.